Cargando…
Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
The cobas(®) EGFR Test provides a semiquantitative index (SQI) that reflects the proportion of mutated versus wild-type copies of the EGFR gene in plasma. The significance of SQI as an indirect measure of the variant allele frequency (VAF) or mutated copies/mL remains unclear. The aim of this study...
Autores principales: | González de Aledo-Castillo, José Manuel, Serhir-Sgheiri, Samira, Calbet-Llopart, Neus, Arcocha, Ainara, Jares, Pedro, Reguart, Noemí, Puig-Butillé, Joan Antón |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392299/ https://www.ncbi.nlm.nih.gov/pubmed/34441254 http://dx.doi.org/10.3390/diagnostics11081319 |
Ejemplares similares
-
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021) -
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019) -
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018) -
cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020) -
cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)